The effect of RESP301 as an add on treatment to SOC will be evaluated for its efficacy in reducing rate of progression to a more severe level of COVID-19 and for safety, by comparison with SOC alone in hospitalized COVID-19 patients.
This is an open-label, randomized, multicenter, parallel group, concurrent, controlled study
using a sequential adaptive design to evaluate the efficacy and safety of RESP301 plus SOC
versus SOC alone in hospitalized patients with COVID-19 (World Health Organization [WHO]
ordinal scale level 3 or 4).
Approximately 300 participants will be enrolled and randomized 2:1 to the Investigational arm
or the Control arm. The study will be divided into the following periods: Screening period:
(up to 2 days), Intervention (up to 10 days), follow-up (Day 14 and Day 28).
Drug: RESP301, a Nitric Oxide generating solution
Product application requires inhalation using a standard handheld nebulizer.
Other: Standard of Care
Participants will receive institutional SOC for the treatment of COVID-19.
Inclusion Criteria:
1. Participant has laboratory-confirmed SARS-CoV-2 infection as determined by reverse
transcriptase polymerase chain reaction (RT-PCR) or other approved clinical testing
prior to randomization.
2. Participant is hospitalized in relation to COVID-19, requiring supplemental oxygen to
maintain SpO2 at a safe level (WHO level 3 & 4).
3. Participant is capable of giving signed informed consent
4. Participant is male or female. All females of childbearing potential, including
pregnant females, must consent to urine pregnancy testing at screening to be eligible
for the study.
Exclusion Criteria:
1. Rapidly deteriorating or likely to require escalation to high flow oxygen, invasive or
non-invasive ventilatory support within 24 hours according to Investigator's opinion.
2. Unable to safely receive a nebulized treatment for approximately 8 minutes according
to Investigator's opinion.
3. Unable to receive or considered ineligible for invasive or non-invasive ventilatory
support.
4. History of methemoglobinemia.
5. Presence of uncontrolled asthma, history of severe bronchospasm.
6. Presence of severe chronic respiratory disease and tracheostomy.
7. Suspected or confirmed untreated, active tuberculosis.
8. Severely immune-compromised participants in Investigator's opinion.
9. Recent active coronary artery disease or decompensated heart failure.
Imperial College Healthcare NHS Trust, St. Mary's Hospital
London, United Kingdom
Royal Preston Hospital
Preston, United Kingdom